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In recent years, cancer has come to be thought of as a metabolic disease.  The Warburg 
phenotype, characteristic of most cancer cells is postulated to confer survival advantages. 
Special attention has been paid to treatments that attenuate metabolic function in cancer. 
Docosahexaenoic Acid (DHA; 22:6; 6n-3) has been shown to depress mammary 
carcinoma survival in cell culture as well as animal models.  DHA supplementation has 
been shown to diminish the bioenergetic profile of malignant cell lines in a dose 
dependent manner.  In the current study, the location of DHA’s impact on oxidative 
phosphorylation will be investigated. This research will help to discern a possible 
mechanism for DHA, thus allowing for a more targeted approach in the search for 
compounds which may synergistically interact with DHA to inhibit cancer cell growth 
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Breast cancer is the second highest cause for cancer-related mortality in the 
United States, and over 231,840 women are estimated to be diagnosed in 2015 [1].  
Although it has been almost a century since Otto Warburg observed a decrease in 
mitochondrial respiration and oxidative phosphorylation in favor of a glycolytic 
phenotype in cancer, it is only recently that cancer is being considered as a metabolic 
disease [2].  Importantly, the functional state of the mitochondria plays a critical role in 
carcinogenic invasion and metastasis because it has been shown to help stabilize the 
Warburg phenotype [3]. Although the majority of cancers exhibit a Warburg phenotype, a 
small subset of aggressive cancers display a mitochondrial phenotype which is heavily 
reliant on mitochondrial oxidative phosphorylation for energy.    
 It has been shown that hypoxia inducible factor 1α (HIF-1α) is at least partially 
responsible for altering the metabolic switch observed in cancer. Under normal 
conditions, HIF-1α mediates that adaptation of cells to hypoxic condition.  However, in 
many cancers, HIF -1α has been shown to be stabilized even under normoxic conditions 
[4].  Studies have shown a correlation between poor prognosis [5], tumor aggressiveness 
[6], and early relapse [7] with increased HIF activity.  
 The importance of mitochondrial function in stabilizing cancer phenotype has led 
to the study of metabolic inhibitors as potential cancer therapeutics.  For example, the 
mitochondrial targeted drugs MitoQ and Mito-CP have been shown do decrease cancer 
proliferation in vitro by lowering cellular ATP levels [8].  Additionally, dietary 
polyunsaturated fatty acids, in particular docosahexaenoic acid (DHA) and 
eicosapentaenoic acid (EPA), have been shown to have anticancer properties.  Recently, 
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it was shown that dietary treatment with DHA attenuates the bioenergetics profile of 
tumors by altering HIF-1α activity [9].  DHA has also been used in combination with the 
glycolytic inhibitor 2-deoxyglucose (2DG) to synergistically trigger cancer cell death 
[10].  However, no study has yet been performed that characterizes the combined effects 
of MTDs and DHA on cellular metabolism. Additionally, both MTDs and DHA are 
known to decrease cellular oxidative phosphorylation, but the location and mechanism 
underlying this effect is not well characterized.   The current study is designed to 
elucidate the site at which DHA affects cellular respiration.  Oxidative phosphorylation is 
carried out by a series of four protein complexes (I-IV) that are located in the inner 
mitochondrial membrane.  A clark-type electrode will be employed to measure oxygen 
consumption in the presence and absence of specific mitochondrial inhibitors and 
substrates in order to determine specific activity and location of the DHA effect within 
each of the four complexes.   In order to test this hypothesis, two metabolically distinct 
breast cancer cell lines will be employed. (1) BT-474, with a mitochondrially active 
phenotype, and (2) MDA-MB-231, with a glycolytically active (Warburg) phenotype.  A 
non-transformed breast epithelial MCF-10A cell line will be used as a control.  Together 
the data should help advance our current understanding of the root cause of DHA induced 
cancer bioenergetic reprogramming as well as provide evidence as to the possible 








Cell Lines & Reagents 
BT-474 mammary ductal carcinoma, MDA-MB-231 adenocarcinoma, and MCF-10 non-
transformed cells were purchased from ATCC (Manassas, VA).  Docosahexaenoic acid 
(DHA; C22:6n-3) was purchased from Sigma (Sigma, St. Louis, MO) and dissolved in 
ethanol (EtOH), flushed with nitrogen gas, protected from light and stored at -20°C for 
no more than 60 days.  
 
Cell Culture 
BT-474 cells were maintained in HybriCare (ATCC) supplemented with 10% fetal 
bovine serum (FBS; Hyclone, Logan, UT). MDA-MB-231 cells were maintained in 
RPMI-1640 (Thermo Scientific, Rochester, NY) supplemented with 10% FBS (Hyclone, 
Logan, UT). MCF-10A cells were maintained in DMEM/F12 (Thermo Scientific, 
Rochester, NY) supplemented with 5% FBS (Hyclone). Cells were grown as monolayers 
at 378C in a humidified environment with 5% CO2.   
Aerobic Metabolism Assay 
The partial pressure of oxygen (P02) in an oxygraph pig was measured using an YSI 
Model 5300 Biological Oxygen Monitor equipped with a platinum Clark electrode. 3.0 x 
106 BT-474 cells were seeded in 10 mL of cell culture medium at 37°C prior to treatment.  
The cells were treated with DHA or an equal volume of EtOH 48 hours prior to the 
experiment. Non-treated cells were used as a control.  The cells were trypsinized, 
counted, and resuspended in 37°C phosphate buffered saline (PBS) to a final 
concentration of 3.0 x 104 cells/ul. 100 ul of cell suspension was injected into a pig 
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containing 180 ul PBS equilibrated to 37°C. The rate of change in P02 was determined 
following successive treatments of glycolytic or mitochondrial inhibitors and electron 
donors. A complete profile of stepwise controlled ETC – complex linked metabolism 
would be generated by adding compounds in the following order: 2-deoxyglucose (2-
DG), oligomycin A, carbonyl cyanide 4-trifluoromethoxy-phenylhydrazone (FCCP), 
glutamate and malate, rotenone, succinate, malonate, glycerol-3 phosphate (G3P), 
antimycin A,  N,N,N’,N’-tetramethyl-1,4-benzenediamine dihydrochloride (TMPD) with 
ascorbate, and cyanide.  
 
Inhibitor Preparations 
The following stock solutions were prepared in water: 1 mM Rotenone; 1 mM FCCP; 10 
mM Malonate; 10 mM Potassium Cyanide (KCN).  Stock solution of 1 mM Oligomycin 
A and 1.0 mM Antimycin A were prepared in 95% EtOH. All inhibitor solutions were 
stored at -20 °C. 
 
Substrate Preparations 
The following stock solutions were prepared in water: 15 mM glutamate; 2.5 mM malate; 
10 mM succinate; 20 mM Glycerol-3-Phospahte (G3P); and 50 uM ADP.  Solutions of 
10 mM ascorbate and 0.2 mM tetramethyl-p-phenylenediamine (TMPD) were made in 
95% EtOH. All inhibitor solutions were stored at -20 °C. 
 
Cell Viability Assay 
Cells were trypsinized and counted using trypan blue staining and a hemacytometer.  
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Unstained cells were counted as viable 
 
Data Recording and Analysis 























The oxygraph measures real time oxygen concentration in the experimental vessel 
called a “pig.” When cells are added to the pig, cellular oxygen consumption rate (OCR) 
can be estimated by monitoring real time change in oxygen concentration.  OCR can be 
correlated to mitochondrial aerobic respiration. Every cell line has a unique metabolic 
profile that depends on a number of factors. One such factor is cell confluencey during 
tissue culture.  In order to conduct constant and comparable oxygraph experiments an 
optimization control on cell confluencey must be performed.   
 
Figure 1: Cell confluency optimization for oxygraph. BT-474 cells were seeded in T75 
cm2 flasks at various densities.  After 72 hours,3 million cells were resuspended in PBS 




Figure 2:  Oxygen consumption rate dependence on cell confluency. BT-474 cells 
were cultured at various densities and oxygen consumption rate was determined on the 
oxygraph.  Maximal O2 consumption rate was determined using WINDAQ32 data 
analytics software.  
 
BT-474 cells were maintained with different cell densities and examined on the 
oxygraph for consistency (fig. 1) and maximal OCR (fig.2).  6-6.5 x 106 cells display the 
most consistent study system to study BT-474 cells.  All cell counts above and below 6 
million cells show a sharp change in OCR midway through the experiment which 
possibly indicates non-renewable substrate depletion (fig 1). This type of inconsistency is 
undesirable as it introduces unpredictable inconsistencies that would prevent accurate 
analysis of changes in OCR upon substrate addition in future experiments. Additionally, 
these cell concentrations exhibited decreased maximal OCR (fig 2) compared to the 6 
million cell size sample. Results indicate that cells must be grown to a final confluencey 
of approximately 6 million cells per T75 cm2 maintenance flask for optimal consistency 






Figure 3: Two pig optimization. 3 million BT-474 cells from the same culture flask 
were added to two separate pigs and run simultaneously on the oxygraph. Each pig was 
stationed either on (A) different stir plates or (B) on the same stir plate. Oxygen 
consumption rates were recorded simultaneously.   
 
 
A major limitation of using an oxygraph is the number of cells required for each 
experiment. Growing a sufficient number of cells can be both cumbersome and time 
consuming.  Due to the fact that optimal cell confluency was determined to be 6 million 
cells (fig. 1) and 3 million cells are needed to for each experiment, it was realized that 
two experiments could be performed from a single flask of cells.  In order to maximize 
efficiency, two pigs were set up to run in parallel.  At first, the two pigs were placed on 
separate stir plates (fig. 3A).  However, uncorrectable variations in stir bar speed resulted 
in non-comparable OCR readings between the two pigs.  Placing both pigs on the same 
stir plate rectified this difference (fig. 3B).  Effectively setting up two pigs to run in 
parallel doubles throughput for the oxygraph, reducing both cost and time expenditure, 




Table 1:  Agents used to dissect ETC complex activities when using a Clark-type electrode
Agent Description
Glutamate + Malate Measures OCR from combined ETC complexes, I, III, and IV.  Electrons from NADH 
generated from glutamate oxidation by glutamate dehydrogenase enter the respiratory 
chain at complex I.
Rotenone Rotenone is an inhibitor of complex I. Addition of rotenone will recude OCR and show 
other oxygen consuming processes in the system.
Succinate Succinate provides electrons directly to complex II and bypasses complex I of the ETC. 
OCR increase through complex II when cells are exposed to rotenone.
Malonate Malonate competitively inhibits ETC complex II.  Treatment with malonate indicates 
the extent of activity and intacktess of ETC complex II.  Malonate is a reversible 
inhibitor. 
Glycerol-3-Phosphate G3P provides electrons for ETC complex III through the glycerol-phosphate cycle via 
glycerol-3-phosphate dehydrogenase.  G3P bypasses blocked complexes I and II and 
increase OCR even after mitochondria are exposed to rotenone and malonate.
Antimycin A Antimycin A inhibits complex III of the ETC.  Addition of antimycin A after G3P is useful 
for determining OCR activity of ECT complex III.
Ascorbate + TMPD TMPD is an artificial electron donor to ETC complex IV and ascorbate maintains TMPD in 
a reduced state.  OCR increases through complex IV when mitochondria are also 
exposed to Antimycin A.
KCN KCN irreversibly inhibits complex IV.  Treatment with KCN will decrease OCR down to 
the instruments baseline. 
ADP ADP addition increases OCR in proportion to ADP addition when the ETC is coupled to 
ATP synthesis. 
FCCP ETC uncouples that dissapates mitochondrial inner membrane potential by acting as a 
protein ionophore that triggers nonspecific proton leak. FCCP is used to assess maximal 
respiratory capacity. 
Oligomycin A Oligomycin A is an antibiotic that blocks complex V (ATP synthase) of the ETC.   
*Table was adapted from (Hong et al. 2012) 
 
 
Specific mitochondrial inhibitors and substrates can be added to cells in order to 
stop or stimulate electron flow through each complex of the electron transport chain 
(Table 1).  When added to cells in an oxygraph, these compounds can be used to 
determine the activity and intactness of each individual complex of the ETC.  
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Figure 4: Mitochondrial substrates test. 3 million BT-474 cells were run in the 
oxygraph. The following substrates were added to A: (1) 20 uL 2-DG; (2) 100 uL Malate 
+ Glutamate; (3) 100 uL Oligomycin A; (4) 100 uL FCCP and B: (1) 40 uL ADP; (2) 100 
uL Glutamate + Malate; (3) 100 uL Rotenone; (4) 100 uL Succinate. Samples were run 
simultaneously.  
  
 To test the activity of mitochondrial targeted compounds, various substrates and 
inhibitors were added to untreated BT-474 cells (Fig 4A and 4B).  Interestingly, none of 
the compounds worked as expected.  Additions of 2-DG, Malate, Glutamate, FCCP, and 
ADP should have all stimulated OCR and caused the slope of the graph to decrease 
sharply. However, this was not observed. Conversely, Oligomycin A and Rotenone 
should have stopped OCR completely.  Oligiomycin A did not inhibit OCR (Fig 4A) and 
rotenone seemed to actually increase the amount of oxygen present in the pig.  Together 
these results suggest that the mitochondrial compounds are not working properly.  
Possible reasons for improper activity include membrane corruption or poisoning by 
substrate, OCR changes induced by ethanol used to dissolve some compounds, expired or 
defective compounds, or inability of the compound to reach the mitochondria.  









Figure 5: Ethanol’s effect on respiration.  3 million BT-474 cells were run in the 
oxygraph. 95% Ethanol was added consecutively in various concentrations: (1) 10 uL 
EtOH; (2) 25 uL EtOH; (3) 50 uL EtOH. Experiment represents an N=3.  
 
 Some mitochondrial compounds were dissolved in ethanol.  To determine if the 
ethanol was negatively affecting OCR, experiments were performed in which various 
amounts of 95% ethanol were added to untreated BT-474 cells.  Results indicate EtOH 







Figure 6: Digitonin’s effect on respiration. 3 million BT-474 cells were run in parallel 
on the oxygraph. Solution 1 (grey) contained PBS. Solution 2 (black) contained PBS + 
0.003 wt% digitonin.  
 
 Further research into the literature indicated that some mitochondrial substrates 
such as succinate and glutamate are unable to cross the plasma membrane of cells and 
therefore unable to reach the mitochondria, thus preventing them from properly affecting 
OCR.  In an effort to circumvent this limitation, 0.003% digitionin was used to 
selectively permeabilize the plasma membrane. Digitonin is a molecular detergent that 
should allow all mitochondrial compounds to permeate the cellular membrane without 
issue. Before inhibitors could be tested, the effect of digitonin on basal OCR needed to be 
determined (fig. 6).  Results indicate that addition of digitonin to BT-474 cells does not 








Figure 7: Mitochondrial compounds with diginonin permeabilized cells. 3 million 
BT-474 cells were run on the oxygraph. Substrates were added to assess metabolic 
activity: (1) 50 uL Glutamate + Malate; (2) 25 uL Rotenone; (3) 50 uL Succinate; (4) 100 
uL succinate; (5) Stir bar activation for 2 seconds; (6) 100 uL TMPD + Ascorbate; (7) 
100 uL sodium cyanide. Experiment was run simultaneously in duplicate.  
 
 To assess whether digitonin successfully permeabilized the plasma membrane so 
that the mitochondrial compounds could enter the cell, a gambit of substrates were tested 
with cells treated with 0.003% digitonin (fig. 7). Results indicate that the permiabilization 
of the cell membrane with digitonin was not sufficient to alter results upon the addition of 
most substrates. It is unclear if this is due to a possible sustained inability of substrates to 
penetrate the membrane. However, the slight increase of OCR upon succinate addition, 
and the drastic increase thereof with TMPD + ascorbate addition indicate that the 





Figure 8: DHA’s effect on complex IV activity. 4 million BT-474 cells were cultured 
with 165 uM DHA 48 hours prior to being run on the oxygraph.  Substrates were added 
to determine metabolic activity: (1) 100 uL Rotenone; (2) 100 uL antimycin A; (3) 100 
uL TMPD; (4) 100 uL Ascorbate; (5) 100 uL Sodium Cyanide. OCR was monitored 
simultaneously in DHA treated (A) and untreated (B) cells.   
 
 Activity of Complex IV of the electron transport chain activity in DHA treated 
and non-treated cells was assessed using the  oxygraph.  Rotenone and Antimycin A were 
added to block complex I and III respectively. TMPD and ascorbate are able to bypass 
complexes I, IIand III and feed electrons directly to complex IV.  Adding rotenone and 
antiymicn A before TMPD and ascorbate ensures that all observed oxygen consumption 
is a result of activity directly though complex IV.  When comparing treated to non-treated 
cell lines, the effect of TMPD and ascorbate were virtually identical.  Following 
treatment with complex IV substrate, the DHA treated cells maintained an OCR of 2.78 
% oxygen/min/3.0 x106 cells with the non-treated cells respired at 2.81 % 
oxygen/min/3.0 x106 cells.  The identical values of these slopes indicate that that activity 
of complex IV is conserved between treated and non-treated cells which suggests that the 
decreased activity of oxidative phosphorylation seen upon DHA treatment is upstream of 








Figure 9: TMPD and Ascorbate Positive Control.  OCR was monitored upon addition 
of (1) 100 uL TMPD and (2) 100 uL Ascorbate in the absence of cells.  
 
 In order to eliminate all possible confounds, a negative control in which TMPD 
and ascorbate were added to an oxygraph pig in the absence of cells.  Surprisingly, 
addition of both TMPD and ascorbate caused the appearance of oxygen consumption.  
This result should not have been possible without cells present.  While the OCR did not 
continue ad infinatum, this lends a generous amount of doubt into the results seen earlier 
in figure 8.  It is impossible to know if the increased oxygen consumption was due only 
to complex IV activity or whether the TMPD and ascorbate mimicked OCR by some 
other means.  Essentially, this control rendered all previous experiments performed with 









 The Oxygraph is a Clark-electrode type that can accurately determine the activity 
and intactness of each protein complex in the electron transport chain (ETC) of the 
mitochondria.  It is advantageous over other metabolic profile measuring techniques in 
that it is flexible in measuring mitochondrial function, can accommodate a large number 
of substrate and inhibitor additions, and is relatively inexspensive.  However, it is 
difficult to get the oxygraph to work properly in a consistent manner.  A large amount of 
optimization and calibration must be performed in order to ensure it is working properly 
(fig. 1, 3-10). Additionally, sometimes oxygen leaks from the apparatus causing the 
oxygen consumption profile to read inaccurately and some drugs are not easily removed 
from the chamber and residues could potentially affect OCR.  Furthermore, some drugs 
or solutions may even directly interact with the silver electrode to give the illusion that 
oxygen concentration is changing. For example, TMPD and ascorbate were shown to 
induce the appearance of oxygen consumption even in the absence of cells (fig. 9).  
While the ultimate change in oxygen concentration was not extreme and did level out 
over time, this inconsistency introduces a level of uncertainty into the results obtained 
when analyzing functionality of complex IV (fig. 8).  TMPD and ascorbate bypass the 
rest of the ETC and donate electrons directly to complex IV.  It appears that addition of 
TMPD and ascorbate stimulates OCR at the same rate in both treated and non-treated 
cells.  This indicates that DHA treatment does not affect electron flow through complex 
IV and that the activity of complex IV is preserved (fig 8.)  However, these results cannot 
be trusted as the change in OCR cannot be definitively proven to be from ETC 
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stimulation instead of background effects seen in fig 9.  
 Another limitation of the oxygraph is the limit of detection, as it has a much more 
narrow range and higher oxygen consumption rate than some newer technologies. 
Furthermore, the oxygraph requires cells be in suspension, which is postulated to change 
signaling and potentially bioenergetics in comparison to new technologies which measure 
OCR directly from the culture vessel.  Originally, this study was designed to compare the 
two metabolically distinct cancer cell types BT-474 and MDA-MB-231 with a non-
transformed cell line MCF-10A.  BT-474s are mitochondrially active, MDA-MB-231 
cells are glycolytically active, and MCF-10As represent a normal phenotype. 
Unfortunately, only the BT-474 cells had sufficiently robust respiration levels to be 
registered on the oxygraph.  Both the MCF-10A and MDA-MB-231 cells did not show 
any oxygen consumption.  The inability to compare results across various cell lines 
severely hampers the integrity of the study.  
 Ultimately, the oxygraph represents a promising and exciting method for 
measuring ETC complex activity.  However, too much optimization of technique is 
required in order to obtain consistent and trustable results.  So far it has not been feasible 
for the BT-474 cells.  All thing are considered, other techniques like the XF24 
extracellular flux analyzer might be a better option to continue this research.  Although 
each run is significantly more expensive on the XF24 analyzer, it has a well-established 
protocol that runs consistently and could save both time and money by reducing the 
amount of optimization that needs to be done.  
 
Mitochondria and Cancer 
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 Otto Warburg was the first person to recognize that cancer cells prefer using 
aerobic glycolysis over oxidative phosphorylation to generate ATP.  Recent studies 
indicate that carcinogenesis might be a result of this deregulated cellular metabolism 
[11].   Numerous studies show that cancer cells have a structurally unstable or non-
functional mitochondrial that are unable to generate sufficient levels of ATP to maintain 
cellular needs [12-16].   New focus has been applied on compounds that target cancer 
metabolism as a method of treatment.   
Dietary lipids have been extensively studied in association with breast cancer 
survival and recurrence [17]. Specifically, the balance and source of dietary lipids have 
been shown to play an important role in cancer risk [18].  Omega-3 Polyunsaturated fatty 
acids (PUFA) have been shown to positively reduce malignant transformation, 
angiogenesis, and tumor cell growth in cell culture.  Of the omega-3 PUFAs, 
docosahexaenoic acid (DHA) and eicosapentanoic acid (EPA) are thought to exhibit the 
largest anti-cancer effects.  Recent studies have shown that treatment with DHA 
decreases ATP production through both glycolysis and oxidative phosphorylation in 
mammary cancer cells [11].  Importantly, maximal oxygen consumption rate has been 
shown to be decreased upon DHA treatment, indicating that DHA significantly alters the 
activity of the ETC whether directly or through a metabolite.   
There are various mechanisms through with DHA could be exhibiting its effects. 
DHA could be altering global ETC function by altering the fatty acid composition of the 
mitochondrial membrane. DHA is a long chain PUFA with six double bonds.  It is 
thought to adopt a kinked 3-dimensional structure which causes an increase in membrane 
fluidity upon DHA treatment.  In the plasma membrane, incorporation of DHA has been 
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shown to disrupt lipid rafts and alter cellular signaling [20] It is postulated that 
mitochondria might contain lipid raft like domains that help organize proteins in the inner 
mitochondrial membrane.  It is possible that DHA could be interfering with these 
mitochondrial domains in a similar fashion thus altering metabolic function [20]. 
Evidence indicates that in the mitochondria, dietary fish oil induces uncoupled respiration 
(proton leak) in colon cancer cells [21].  This may be a result of DHA preferentially 
incorporating into mitochondrial cardiolipin [22], [23]. Because the ETC relies upon a 
proton gradient to generate ATP, it is possible that DHA incorporation into mitochondrial 
membrane induces proton leak in the mitochondrial membrane and therefore decreases 
maximal respiratory capacity.  This theory might also explain why DHA treatment results 
in increased in reactive oxygen species (ROS) because most cellular reactive oxygen 
species are generated as electrons leak out of the ETC and interact directly with oxygen.   
It is also possible that DHA affects the ETC by acting through electron 
transferring flavoproteins (ETF).  ETFs are soluble mitochondrial matrix proteins that 
utilize energy generated from β-oxidation of fatty acids (like DHA) to transfer electrons 
directly to complex III of the ETC.  It is possible that DHA treatment alters the 
functionality of ETFs thereby decreasing overall oxygen consumption capacity although 
the activity of EFTs have never been studied in relation to DHA supplementation.  
As discussed above, results indicate that the activity and intactness of complex IV 
is unaffected by DHA treatment (fig. 8).  If DHA were significantly altering 
mitochondrial membrane fluidity and causing electron leak, the OCR from DHA treated 
cells would be significantly slower than non-treated cells.  However, this was not the 
case, implying that DHA works via a focused effort on a specific ETC complex or 
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combination of complexes instead of affecting the entire ETC by altering membrane 
functionality.  Unfortunately, due to the questionable nature of the control (fig. 10) it is 
impossible to declare for certain whether complex IV really wasn’t affected by DHA 
treatment.  
As a benign dietary substance, DHA treatment may be used as an effective non-
invasive therapy.  Previous data show that DHA coordinates integrated targeting of major 
signal-transduction pathways and metabolism in parallel [9]. DHA is not powerful 
enough to treat cancer on its own. However, it can be used as a useful supplement to 
enhance other treatments. DHA has been shown to enhance efficacy in combination with 
chemotherapies [24].  For example, unpublished data from our lab indicates that 
combination treatments with 2-DG and DHA enhanced metabolic injury to the cancer 
cells (unpublished data).  A better understanding of the mechanism by which DHA acts 
will help us be able to better identify metabolically targeted compounds that could 
synergize with DHA providing innovative new strategies in combination therapies to 
target cell metabolism.   
 
Future Directions 
The next step of this project will be to finish optimizing the oxygraph. Or, if that 
proves impossible, move on to another technique such as single flow mitochondrial 
analysis or XF24 extracellular flux analysis to determine the locus at which DHA acts on 
the ETC.  Once DHA’s mechanism of action is identified, studies will be performed with 
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